An Inducible, Isogenic Cancer Cell Line System for Targeting the State of Mismatch Repair Deficiency

Open Access

Peer-reviewed

Research Article

Julie M. Bailis ,

* E-mail: jbailis@amgen.com

Affiliation Oncology Research, Amgen Inc., South San Francisco, California, United States of America
⨯
Marcia L. Gordon,

Affiliation Oncology Research, Amgen Inc., Seattle, Washington, United States of America
⨯
Jesse L. Gurgel,

Affiliation Oncology Research, Amgen Inc., Seattle, Washington, United States of America
⨯
Alexis C. Komor,

Affiliation Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, United States of America
⨯
Jacqueline K. Barton,

Affiliation Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, United States of America
⨯
Ilan R. Kirsch

Affiliation Oncology Research, Amgen Inc., Seattle, Washington, United States of America
⨯

Reader Comments (0)

Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
Rhodium
Is the Subject Area "Rhodium" applicable to this article?

Thanks for your feedback.
Lung and intrathoracic tumors
Is the Subject Area "Lung and intrathoracic tumors" applicable to this article?

Thanks for your feedback.
Doxycycline
Is the Subject Area "Doxycycline" applicable to this article?

Thanks for your feedback.
Cell viability testing
Is the Subject Area "Cell viability testing" applicable to this article?

Thanks for your feedback.
DNA damage
Is the Subject Area "DNA damage" applicable to this article?

Thanks for your feedback.
Renal cancer
Is the Subject Area "Renal cancer" applicable to this article?

Thanks for your feedback.
Mismatch repair
Is the Subject Area "Mismatch repair" applicable to this article?

Thanks for your feedback.